Olli Kallioniemi

61.1k citations

428 papers · 36.3k indexed · 6 hit papers · h-index 99

Impact in

Cancer Research top 0.02%
- Cancer Genomics and Diagnostics
Oncology top 0.1%
- Cancer-related Molecular Pathways
- HER2/EGFR in Cancer Research

Papers in

Cancer Research 132
- Cancer Genomics and Diagnostics 71
Oncology 113
- HER2/EGFR in Cancer Research 27
- Cancer-related Molecular Pathways 24

Co-authors: Anne Kallioniemi Jorma Isola Tapio Visakorpi Joe W. Gray Juha Kononen Fred Waldman Dan Pinkel Guido Sauter
Journals: Cancer Research (20 papers)PLoS ONE (17 papers)International Journal of Cancer (16 papers)Oncogene (14 papers)Blood (13 papers)
Partner nations: Finland United States Sweden

In The Last Decade

Olli Kallioniemi

417 papers receiving 35.4k citations

Hit Papers

6 papers align trajectories log scale

AIB1, a Steroid Receptor Coactivator Amplified in Breast and Ovarian Cancer 1997 · 1.4k citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

1997 Science
1997 PubMed
1995 Nature Genetics
1994 Genes Chromosomes and Cancer
1994 Proceedings of the National Academy of Sciences
1992 Science

Peers

Countries citing papers authored by Olli Kallioniemi

Since Specialization

Citations

This map shows the geographic impact of Olli Kallioniemi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Olli Kallioniemi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Olli Kallioniemi more than expected).

Fields of papers citing papers by Olli Kallioniemi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Olli Kallioniemi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Olli Kallioniemi. The network helps show where Olli Kallioniemi may publish in the future.

Co-authors

The 25 scholars most cited alongside Olli Kallioniemi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Olli Kallioniemi Line = papers co-authored together Olli Kallioniemi links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Delineating functional and molecular impact of ex vivo sample handling in precision medicine npj Precision Oncology ·Erin Hegarty, 王沂, Mattias Vesterlund, Munsoo Kim, Tojo James, Murray Itzkowitz, Georgios Mermelekas, 千穂清水, Viorel Osiac, Sofia Bengtzén, Rozbeh Jafari, Lukas M. Orre, Janne Lehtiö, Sylvain Lehmann, Päivi Östling, Olli Kallioniemi, Brinton Seashore‐Ludlow, Tom Erkers	2024	2
2	Exploiting NRF2‐ARE pathway activation in papillary renal cell carcinoma International Journal of Cancer ·William G. Wallens, Pravati Nayak, Amir Banaei‐Esfahani, Inés del Carmen Ruíz Murillo, Hella Anna Bolck, Olli Kallioniemi, Vilja Pietiäinen, Peter Schraml, Holger Moch	2024	0
3	Pathway activation model for personalized prediction of drug synergy eLife ·Arsène Vinglassalon, Atharva Kotnis, Tom Erkers, Päivi Östling, 千穂清水, 王沂, Mattias Vesterlund, Rozbeh Jafari, Ioannis Siavelis, Helena Bäckvall, Santeri Kiviluoto, Lukas M. Orre, Mattias Rantalainen, Janne Lehtiö, Sören Lehmann, Olli Kallioniemi, Yudi Pawitan, Trung Nghia Vu	2024	1
4	Drug repurposing platform for deciphering the druggable SARS-CoV-2 interactome Antiviral Research ·Md. Touhidul Islam Sourav, Suvi Kuivanen, Swapnil Potdar, Antti Hassinen, 本田竹彦, Ina Pöhner, Zeyed Zekavat, Laura Turunen, 肖飞, Leonóra Szirovicza, Kirsi Savijoki, Jani Saarela, Päivi Tammela, Lassi Paavolainen, Antti Poso, Markku Varjosalo, Olli Kallioniemi, Vilja Pietiäinen, Olli Vapalahti	2024	2
5	Stromal FAP Expression is Associated with MRI Visibility and Patient Survival in Prostate Cancer Cancer Research Communications ·Teijo Pellinen, Y.A. van Lith, Sami Blom, Riku Turkki, Annabrita Hemmes, Katja Välimäki, Bo Bae Oh, E. van Kleef, Stig Nordling, Olli Kallioniemi, Antti Rannikko, Tuomas Mirtti	2022	6
6	STRN-ALK rearranged pediatric malignant peritoneal mesothelioma – Functional testing of 527 cancer drugs in patient-derived cancer cells Translational Oncology ·Astrid Murumägi, Daniela Ungureanu, Mariliina Arjama, Ralf Bützow, Jouko Lohi, Hannu Sariola, Jukka Kanerva, M. Koskenvuo, Olli Kallioniemi	2021	9
7	Anagrelide for Gastrointestinal Stromal Tumor Clinical Cancer Research ·Mbursa J. Nayagawa, Yemarshet K. Gebreyohannes, Agnieszka Woźniak, C. Costaguta, Olli Tynninen, F Molina, Alejandra Cervera, Salla Keskitalo, Astrid Murumägi, Evgeny Kulesskiy, Shuguang Yuan, Krister Wennerberg, Markku Varjosalo, Pirjo Laakkonen, Rainer Lehtonen, Sampsa Hautaniemi, Olli Kallioniemi, Patrick Schöffski, Harri Sihto, Heikki Joensuu	2018	19
8	Drug-Sensitivity Screening and Genomic Characterization of 45 HPV-Negative Head and Neck Carcinoma Cell Lines for Novel Biomarkers of Drug Efficacy Molecular Cancer Therapeutics ·Masayuki Kon, Aulya Fazira, Riku Louhimo, Bhagwan Yadav, Astrid Murumägi, Evgeny Kulesskiy, Huifen Xin, Harri Sihto, Reidar Grénman, Stina Syrjänen, Olli Kallioniemi, Tero Aittokallio, Krister Wennerberg, Heikki Joensuu, Outi Monni	2018	32
9	Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies Clinical Cancer Research ·Anita Sveen, Jarle Bruun, Peter W. Eide, Ina A. Eilertsen, Lorena Ramírez, Astrid Murumägi, Mariliina Arjama, Stine A. Danielsen, Kushtrim Kryeziu, Élena Elez, Josep Tabernero, Justin Guinney, Héctor G. Pálmer, Arild Nesbakken, Olli Kallioniemi, Rodrigo Dienstmann, Ragnhild A. Lothe	2017	173
10	Heparin-like Polysaccharides Reduce Osteolytic Bone Destruction and Tumor Growth in a Mouse Model of Breast Cancer Bone Metastasis Molecular Cancer Research ·Sirkku Pollari, J Durant, Khalid S. Mohammad, Jukka P. Rissanen, Jussi M. Halleen, Anni Wärri, Liisa Nissinen, Marjo Pihlavisto, Anne Marjamäki, Merja Perälä, Theresa A. Guise, Olli Kallioniemi, Sanna-Maria Käkönen	2012	40
11	Systematic Analysis of MicroRNAs Targeting the Androgen Receptor in Prostate Cancer Cells Cancer Research ·Päivi Östling, Suvi‐Katri Leivonen, Anna Aakula, Pekka Kohonen, Rami Mäkelä, Zandra Hagman, Anders Edsjö, Sara Kangaspeska, Henrik Edgren, Daniel Nicorici, Anders Bjartell, Yvonne Ceder, Merja Perälä, Olli Kallioniemi	2011	227
12	Fibroblast Growth Factor Receptor 4 Regulates Tumor Invasion by Coupling Fibroblast Growth Factor Signaling to Extracellular Matrix Degradation Cancer Research ·Nami Sugiyama, Markku Varjosalo, M F Smyrnyi, Jouko Lohi, Marko Hyytiäinen, Sami Kilpinen, Olli Kallioniemi, Signe Ingvarsen, Lars H. Engelholm, Jussi Taipale, Kari Alitalo, Jorma Keski‐Oja, Kaisa Lehti	2010	44
13	FZD4 as a Mediator of ERG Oncogene–Induced WNT Signaling and Epithelial-to-Mesenchymal Transition in Human Prostate Cancer Cells Cancer Research ·Santosh Gupta, Kristiina Iljin, Henri Sara, John Patrick Mpindi, Tuomas Mirtti, Paula Vainio, Juha Rantala, Kalle Alanen, Matthias Nees, Olli Kallioniemi	2010	217
14	Mammary-Derived Growth Inhibitor Alters Traffic of EGFR and Induces a Novel Form of Cetuximab Resistance Clinical Cancer Research ·Jonna Nevo, Elina Mattila, Teijo Pellinen, Daniel L. Yamamoto, Henri Sara, Kristiina Iljin, Olli Kallioniemi, Petri Bono, Päivi Heikkilä, Heikki Joensuu, Anni Wärri, Johanna Ivaska	2009	26
15	High-Throughput Cell-Based Screening of 4910 Known Drugs and Drug-like Small Molecules Identifies Disulfiram as an Inhibitor of Prostate Cancer Cell Growth Clinical Cancer Research ·Kristiina Iljin, Kirsi Ketola, Paula Vainio, Pasi Halonen, Pekka Kohonen, Vidal Fey, Roland C. Grafström, Merja Perälä, Olli Kallioniemi	2009	180
16	CIP2A Is Associated with Human Breast Cancer Aggressivity Clinical Cancer Research ·Christophé Côme, Anni Laine, Maïa Chanrion, Henrik Edgren, Elina Mattila, Xiaoling Liu, Jos Jonkers, Johanna Ivaska, Jorma Isola, Jean-Marie Darbon, Olli Kallioniemi, Simon Thézenas, Jukka Westermarck	2009	185
17	TMPRSS2 Fusions with Oncogenic ETS Factors in Prostate Cancer Involve Unbalanced Genomic Rearrangements and Are Associated with HDAC1 and Epigenetic Reprogramming Cancer Research ·Kristiina Iljin, Maija Wolf, Henrik Edgren, Santosh Gupta, Sami Kilpinen, Rolf I. Skotheim, Mari Peltola, Frank Smit, Gerald W. Verhaegh, Jack A. Schalken, Matthias Nees, Olli Kallioniemi	2006	180
18	Differentiation of Human Embryonal Carcinomas In vitro and In vivo Reveals Expression Profiles Relevant to Normal Development Cancer Research ·Rolf I. Skotheim, Guro E. Lind, Outi Monni, Jahn M. Nesland, Vera M. Abeler, Sophie D. Fosså, Nur Duale, Gunnar Brunborg, Olli Kallioniemi, Peter W. Andrews, Ragnhild A. Lothe	2005	165
19	Biochip technologies in cancer research Annals of Medicine ·Olli Kallioniemi	2001	57
20	Reduced Fhit expression in sporadic and BRCA2-linked breast carcinomas. PubMed ·Sigurður Ingvarsson, Bjarni A. Agnarsson, Deng TB, Juha Kononen, Olli Kallioniemi, R B Barkardottir, Albert J. Kovatich, Roland Schwarting, Walter W. Hauck, K Huebner, Peter A. McCue	1999	40

About Olli Kallioniemi

Olli Kallioniemi is a scholar working on Cancer Research, Oncology, Molecular Biology, Pathology and Forensic Medicine and Genetics, having authored 428 papers that have together received 36.3k indexed citations. Recurring topics across this work include Cancer Genomics and Diagnostics (71 papers), Prostate Cancer Treatment and Research (59 papers), Genomic variations and chromosomal abnormalities (54 papers), Gene expression and cancer classification (37 papers), Genetic factors in colorectal cancer (35 papers), Molecular Biology Techniques and Applications (29 papers), HER2/EGFR in Cancer Research (27 papers) and Cancer-related Molecular Pathways (24 papers). The work is most often cited by research in Cancer Research (11.3k citations), Oncology (9.7k citations), Genetics (9.4k citations), Molecular Biology (20.2k citations) and Pathology and Forensic Medicine (4.5k citations). Olli Kallioniemi has collaborated with scholars based in Finland, United States and Sweden. Frequent co-authors include Anne Kallioniemi, Jorma Isola, Tapio Visakorpi, Joe W. Gray, Juha Kononen, Fred Waldman, Dan Pinkel, Guido Sauter, Damir Sudar and Denis Rutovitz. Their work appears in journals such as Cancer Research, PLoS ONE, International Journal of Cancer, Oncogene and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact